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AML1, the Target of Multiple Chromosomal
Translocations in Human Leukemia, Is Essential
for Normal Fetal Liver Hematopoiesis
Tsukasa Okuda,*² Jan van Deursen,³ Scott W. Hiebert,² 1993). AML1±ETO retains the ability to interact with the
enhancer core DNA sequence and has been shown toGerard Grosveld,³ and James R. Downing*²
interfere with AML1-dependent transactivation (Meyers*Department of Pathology and Laboratory Medicine
et al., 1993, 1995). Thus, transformation by AML1±ETO²Department of Tumor Cell Biology
may result from altered transcriptional regulation of nor-³Department of Genetics
mal AML1 target genes.St. Jude Children's Research Hospital
This concept was further supported by the recentMemphis, Tennessee 38105
characterization of several additional myeloid leukemia±
associated translocations involving the AML1±CBFb
transcription factor complex. The inv(16), which ac-Summary
counts for 15%±18% of cases of de novo AML, results
in the fusion of CBFb to a smooth muscle myosin heavyThe AML1±CBFb transcription factor is the most fre-
chain gene, MYH11, and produces a chimeric productquent target of chromosomal rearrangements in hu-
that retains its ability to interact with AML1 (Liu et al.,man leukemia. To investigate its normal function, we
1993; Shurtleff et al., 1995a). CBFb±MYH11-mediatedgenerated mice lacking AML1. Embryos with homozy-
transformation has been shown to result, in part, fromgous mutations in AML1 showed normal morphogene-
direct inhibition of AML1-regulated transcriptional activ-sis and yolk sac±derived erythropoiesis, but lacked
ity (Hajra et al., 1995a, 1995b). In addition, three alterna-fetal liver hematopoiesis and died around E12.5. Se-
tive AML1-containing fusion products, each retainingquentially targeted AML12/2 ES cells retained their ca-
the complete RHD, are formed by the t(3;21), whichpacity to differentiate into primitive erythroid cells in
occurs in rare cases of myelodysplasia and blast trans-vitro; however, no myeloid or erythroid progenitors of
formation of chronic myelogenous leukemia (Nucifora etdefinitive hematopoietic origin were detected in either
al., 1993, 1994; Mitani et al., 1994). In this translocation,the yolk sac or fetal livers of mutant embryos. More-
AML1 is fused with either the EVI1 gene, which encodesover, this hematopoietic defect was intrinsic to the
a known zinc finger±containing transcription factor, orstem cells in that AML12/2 ES cells failed to contribute
either of two alternative genes of unknown function,to hematopoiesis in chimeric animals. These results
EAP and MDS1, which are located adjacent to EVI1 onsuggest that AML1-regulated target genes are essen-
chromosome 3 (for review see Nucifora and Rowley,tial for definitive hematopoiesis of all lineages.
1995).
Although these early results suggested that AML1 al-
Introduction terations were limited to leukemia of myeloid lineage,
recent studies have demonstrated that AML1 is fre-
The investigation of leukemia-associated translocations quently mutated in pediatric B progenitor acute lymph-
has provided insights into the mechanisms of transfor- oblastic leukemia (ALL), the most common malignancy
mation in human leukemia and has led to the identifica- seen in children (Pui, 1995). Cloning of the ALL-associ-
tion of a series of transcription factors implicated in ated t(12;21) revealed the formation of a chimeric gene
the regulation of normal hematopoiesis (Rabbitts, 1994). that encoded a fusion protein consisting of the N-termi-
The most frequent target of these translocations is the nal helix-loop-helix domain of TEL, a member of the Ets-
acute myeloid leukemia 1 (AML1)±core-binding factor b like family of transcription factors, fused to nearly the
(CBFb) heterodimeric transcription factor complex (Miy- complete AML1 protein, including the RHD and C-termi-
oshi et al., 1991; Erickson et al., 1992; Nisson et al., nal domains (Golub et al., 1995; Romana et al., 1995a).
1992; Nucifora et al., 1993; Mitani et al., 1994; Golub et Analysis of a large number of pediatric ALL cases dem-
al., 1995; Liu et al., 1993). AML1 is a member of a family onstrated expression of the TEL±AML1 chimeric tran-
of transcription factors with homology to the Drosophila script in z25% of cases with a B progenitor immuno-
pair-rule gene runt and directly binds the enhancer core phenotype, despite the complete lack of cytogenetic
DNA sequence TGT/cGGT, which is present in a number evidence of this translocation in the majority of cases
of different viral and cellular promoters and enhancers (Romana et al., 1995b; Shurtleff et al., 1995b). Thus,
(Daga et al., 1992; Erickson et al., 1992; Kagoshima et taken together, these data suggest that alteration of
al., 1993; Meyers et al., 1993; Manley et al., 1993). AML1 transcriptional cascades mediated by AML1 isone of the
binds DNA via a central 118 amino acid Runt homology most common mechanisms of transformation in human
domain (RHD), and its DNA binding affinity is increased leukemia.
by heterodimerization through the RHD with CBFb (Mey- AML1 binds the enhancer core motif that is present
ers et al., 1993; Wang et al., 1993; Ogawa et al., 1993a). in the transcriptional regulatory region of a number of
AML1 was identified through its involvement in the different hematopoietic-specific genes, including the T
AML-associated t(8;21), which occurs in z15% of de cell antigen receptors (Prosser et al., 1992; Redondo et
novo cases (Miyoshi et al., 1991). In this translocation, al., 1992; Wang et al., 1993; Hsiang et al., 1993), the
AML1, including its RHD, fuses to a zinc finger± myeloid-specific gene myeloperoxidase (Nuchprayoon
containing putative transcription factor, ETO, on chro- et al., 1994), and a variety of cytokines and their re-
mosome 8 to form an AML1±ETO chimeric product (Er- ceptors, including granulocyte±macrophage colony-
stimulating factor (GM-CSF) (Takahashi et al., 1995),ickson et al., 1992; Nisson et al., 1992; Miyoshi et al.,
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interleukin-3 (IL-3) (Shoemaker et al., 1990), and the col-
ony-stimulating factor 1 (CSF1) receptor (Zhang et al.,
1994). The enhancer core motif is necessary for the
tissue-specific expression of these genes, but cannot
confer tissue specificity to a heterologous promoter. In
addition, this sequence is in the enhancers of the simian
virus 40 (Weiher et al., 1983), polyoma virus (Kamachi
et al., 1990), and all murine type C retroviruses (Manley
et al., 1993; Sun et al., 1993) and has been shown to
represent a critical regulatory region in several murine
leukemia retroviral enhancers, where it influences tissue
tropism and disease phenotype (Boral et al., 1989; Lo-
Sardo et al., 1990; Speck et al., 1990). Thus, AML1 may
function as a transcriptional organizer that recruits tis-
sue-specific factors to stimulate lineage-restricted tran-
scription. Moreover, recent data suggest that AML1-
mediated transcriptional activity of cellular genes is de-
pendent on sequences adjacent to the enhancer core
motif, with activity only detected using enhancers or
promoters bearing Ets-1- or c-Myb-binding sites near
the AML1 site (Hernandez-Munain and Krangel, 1995;
Wotton et al., 1994).
Cloning of murine CBF (Wang et al., 1993) and poly-
oma enhancer-binding protein (PEBP2) (Ogawa et al., Figure 1. Targeted Disruption of Murine AML1 Gene by Homolo-
1993b; Bae et al., 1993), coupled with low stringency gous Recombination
hybridization with an AML1 cDNA fragment (Levanon (A) Schematic representation of the AML1 cDNA and partial restric-
et al., 1994), revealed a family of closely related DNA- tion map of the AML1 genomic locus with the targeting construct
depicted below. The DNA-binding RHD is shown, as are SacI, SpeI,binding proteins AML1 (PEBP2-B), AML2 (PEBP2-C),
and XbaI (X) restriction sites. The arrows indicate the direction ofand AML3 (PEBP2-A). These proteins show greater than
transcription of the hygrR (hygr) and TK cassettes. The positions of90% identity within the RHD and 60%±80% identity be-
AML1 exons 3 and 4 are shown as boxes, and their coding se-
tween their C-terminal sequences. AML1 mRNA is de- quences are closed. Wild-type (14 kb) and targeted alleles (16 kb)
tected in all adult tissues, with the highest levels of could be distinguished by Southern blots of XbaI-digested DNA,
expression seen in the thymus, bone marrow, and pe- hybridized with either the indicated 59 or 39 probes.
(B) Southern blot analysis of ES cell clones and E11.5 embryos fromripheral blood (Zhu et al., 1994; Satake et al., 1995;
an AML11/2 intercross. ES cell clones with homologous targetingMiyoshi et al., 1995). By contrast, little is known about
of one AML1 allele contain a 16 kb restriction fragment in additionits expression during embryogenesis or about expres-
to the 14 kb fragment derived from the wild-type allele. Homozygous
sion of the other family members. mutant embryos contain only the 16 kb restriction fragment.
Although the available data suggests that AML1 is
likely to play a pivotal role in the regulation of target
codons are introduced into all three reading frames, andgenes involved in the function of the hematopoietic lin-
thus any AML1 protein formed will lack the RHD andeages, its normal cellular functions remain to be defined.
will be unable to bind DNA or to interact with CBFb.To investigate directly the normal biologic function of
Following electroporation of the targeting construct, ESAML1 in vivo, we generated mice carrying a disrupted
cell clones were grown in the presence of hygrB andAML1 allele using gene targeting in embryonic stem
ganciclovir (GANC), and double-resistant clones were(ES) cells. Mice lacking AML1 died during midembryonic
analyzed by Southern blotting to screen for homologousdevelopment secondary to the complete absence of
recombinants (Figure 1B). Of the 80 hygrBR/GANCR E14fetal liver-derived hematopoiesis. Moreover, homozy-
ES clones obtained, 20 (25%) contained a correctly tar-gous AML1-deficient ES cells failed to contribute to he-
geted AML1 allele. Two independently targeted clonesmatopoiesis inchimeric animals. These findings indicate
with normal ploidy were injected into C57BL/6 blasto-that AML1-regulated target genes are essential for defin-
cysts and gave germline transmission. F1 mice hetero-itive hematopoiesis of all lineages.
zygous for the AML1 mutation appeared normal and
had no discernible differences when compared with
wild-type littermates in their hematocrits, nucleatedResults
blood cell counts, white blood cell differentials, or distri-
bution of peripheral blood lymphocyte subsets as ana-Targeted Disruption of AML1 Results in an
Embryonic Lethal Phenotype in Mice lyzed by fluorescence-activated cell sorting analysis
(data not shown). Heterozygous mice were interbredThe AML1 gene was inactivated using a replacement
vector designed to disrupt the coding sequence of AML1 to generate homozygous mutants, and among the 161
newborn offspring genotyped, no AML12/2 mice wereby replacing the splice acceptor and first 20 bp of the
exon that encodes the central 52 amino acids of the identified, indicating that loss of AML1 is incompatible
with normal embryonic development (Table 1).RHD with a hygromycin B (hygrB) cassette (Figure 1A).
As a consequence of this targeting strategy, termination To confirm that gene targeting into the AML1 locus
AML1 Is Required for Fetal Liver Hematopoiesis
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showed no overt evidence of anemia. Small foci of intra-Table 1. Genotypes of Litters Obtained by Intercrossing
AML11/2 parenchymal hemorrhages within the central nervous
system occurred during careful dissection of severalNumbers of
homozygous mutant live E11.5 embryos; however, allStages Pups 1/1 1/2 2/2 Alive 2/2 Dead
other abnormalities in the AML1-deficient embryos were
E10.5 25 10 9 6 0
confined to the hematopoietic system.E11.5 57 13 29 13 2
E12.5 30 10 13 2 5
E13.5 22 6 13 0 3a
F2 Pups 161 58 103 0 Ð Absence of Fetal Liver Hematopoiesis
in AML1-Deficient Embryosa Degenerated
Detailed microscopic analysis of the yolk sac of E11.5
embryos revealed no significant morphologic differ-
ences between AML1-deficient and control embryos
had resulted in an inactivating mutation, reverse tran- (data not shown). During normal murine embryonic de-
scriptase±polymerase chain reaction (RT±PCR) analysis velopment, the major site of hematopoiesis shifts from
for AML1 transcripts was performed on poly(A)1 RNA the yolk sac to the fetal liver at around E11.5±E12.5.
isolated from viable embryonic day 11.5 (E11.5) whole Microscopic examination of the livers of AML1-deficient
embryos. Amplification of AML1 mRNA was with a set embryos at E11.5 revealed the complete absence of
of AML1-specific oligonucleotide primers that bracket fetal liver±derived hematopoiesis. No erythroid, myeloid,
the position of the hygrB cassette insertion, and PCR or megakaryocyte elements were identified in sections
products were probed with an AML1-specific oligonu- of AML12/2 livers, with only primitive nucleated erythro-
cleotide after Southern blot transfer. As shown in Figure cytes seen within vascular channels and hepatic sinu-
2, no amplifiable AML1 mRNA was detected in the soids (Figure 4A). Moreover, analysis of impression
AML12/2 embryos, whereas this mRNA was observed smears made from livers of AML12/2 embryos confirmed
in control littermates. Thus, the targeting strategy the lack of hematopoietic cells (Figure 4B). In addition,
used resulted in elimination of AML1 mRNA encoding peripheral blood of the AML1-deficient embryos at both
the RHD. E11.5 and E12.5 containedonly nucleated large primitive
To identify the stage of embryonic development at erythrocytes, consistent with a yolk sac origin, and
which the AML1mutation is lethal, E10.5±E13.5 embryos lacked identifiable platelets, which were clearly visible
were analyzed. At E11.5 the majority of AML1-deficient in blood smears from wild-type and heterozygous lit-
embryos (87%) were viable; however, by E12.5, very few termates (Figure 4C).
AML12/2 embryos were found alive (Table 1). Morpho- The observed hematopoietic defect in AML12/2 em-
logic evaluation of embryos at E12.5 revealed extensive bryos suggests that yolk sac±derived primitive hemato-
hemorrhages within the ventricle of the central nervous poiesis was unaffected, but that there was a complete
system and vertebral canal (Figures 3A and 3B). Death block in theestablishment of fetal liver±deriveddefinitive
appeared to occur shortly before or during embryo dis-
hematopoiesis. To examine the hematopoietic activity
section, since mutant embryos were comparable in size
further, we isolated individual yolk sacs and fetal livers
and development to their wild-type and heterozygous
from mutant and control embryos and analyzed them
littermates. Microscopically, thehemorrhages in the mu-
for in vitro hematopoietic colony formation. Yolk sacs
tant animals appeared to originate within the ganglia of
obtained from viable E10.5 embryos were dispersed into
the cranial nerves and extended into the third and lateral
single cell suspensions and cultured in triplicate in 1.2%
ventricles. In addition, hemorrhages occurred within the
methylcellulose in media containing 30% fetal calf se-pericardial space and peritoneal cavity in the majority
rum (FCS) supplemented with human erythropoietin andof AML1-deficient animals (Figure 3C; data not shown).
containing murine stem cell factor, IL-3, and GM-CSF.At E11.5, viable AML12/2 animals were morphologi-
These conditions are optimal for the differentiation ofcally indistinguishable from their littermates except for
multipotential hematopoietic progenitor cells with colo-a slight pallor to the liver (see below). The yolk sac
nies being of definitive hematopoietic origin, since atvessels were easily visualized, and the mutant embryos
this stage of development, no primitive hematopoietic
progenitors aredetected in yolk sacs (Wong et al., 1986).
No hematopoietic colonies of any lineage grew in the
yolk sac cell cultures from AML1-deficient embryos,
whereas 473 6 132 and 525 6 74 total colonies per
yolk sac were detected in cultures from wild-type and
heterozygous littermates, respectively (Table 2). Simi-
larly, hematopoietic progenitorswere completely absent
in E11.5 fetal liver cultures from AML1-deficient em-
bryos, but were readily detected in essentially equal
numbers in cultures from wild-type and heterozygous
Figure 2. RT±PCR Analysis of mRNA from E11.5 Embryos
controls. Thus, in the AML1-deficient animals, progeni-
Total embryo mRNA was isolated and amplified with AML1-specific
tors for definitive hematopoiesis of either erythroid orprimers that bracket the site of targeting in exon 4. RT±PCR amplifi-
myeloid lineages were absent from both the yolk saccation was also performed for the ubiquitously expressed HPRT
mRNA as a control for the presence of amplifiable RNA. and liver. These data suggest that loss of AML1 function
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Figure 3. Phenotypes of E12.5 Control and
AML12/2 Embryos
(A) Appearance of a mutant mouse embryos
(2/2) compared with their control littermate
(1/2). The mutant embryo is equal in size
compared with the control and appears to
have developed normally. The mutant em-
bryo is distinguished, however, by the pres-
ence of hemorrhage within the ventricle of
the brain and vertebral canal.
(B) Sagittal sections of the brains show a
comparable level of development in the con-
trol and mutant embryos; however, in the
AML12/2 embryo, hemorrhages can be seen
within the ganglia of the cranial nerves with
extension into the ventricles.
(C) Sagittal section through the thoracic cav-
ity demonstrates a hemorrhage within the
pericardial space of the AML12/2 embryo.
results either in an intrinsic defect in stem cells or multi- cell clones with normal ploidy and single vector inser-
potential progenitors responsible for establishing defini- tions in the targeted AML1 alleles and three nonhomolo-
tive hematopoiesis or in a defect in the yolk sac and gous recombinants (AML11/2 ES cell clones) with only
fetal liver microenvironment that prevents normal in vivo random integrations of the second targeting vector were
development of these cells. selected for in vitro and in vivo differentiation studies.
The hematopoietic differentiation capacity of these
ES cell lines were assayed by culturing them in vitro asAML12/2 ES Cells Differentiate into Primitive
embryoid bodies. When ES cells are cultured as em-Erythrocytes In Vitro, but Fail to Contribute
bryoid bodies, cells of both the myeloid and erythroidto Hematopoietic Lineages In Vivo
series develop, and the erythroid cells express embry-To define further the hematopoietic defect induced by
onic hemoglobins and thus represent primitive erythro-loss of AML1, we generated ES cells with both AML1
poiesis (Wiles and Keller, 1991). Analysis of 8- toalleles disrupted. An AML11/2 ES cell clone was sub-
10-day-old ES cell cultures from both control and AML1-jected to a second round of gene targeting using the
deficient ES cells revealed numerous hemoglobinizedreplacement vector pKO4-4-neo, which was similar to
embryoid bodies that contained nucleated erythrocytesthat used in the initial targeting of AML1 except that the
(Figure 5). Thus, AML1-deficient ES cells retain the abil-hygrBR gene was replaced by a neomycin resistance
ity to undergo primitive erythroid differentiation in vitro.(neoR) coding sequence. AML11/2 ES cells were electro-
By contrast, after 16 days in culture no monocytes orporated with this construct and selected in media con-
macrophages were seen in the embryoid bodies fromtaining hygrB, G418, and GANC, and triply resistant
AML1-deficient cells, whereas numerous differentiatedclones were analyzed by Southern blotting for evidence
monocytes were present in the control cultures. Theseof homologous recombination. Results of this analysis
data suggest that under these in vitro conditions, lossrevealed that 20% of triply resistant clones had under-
of AML1 also impairs monocytic differentiation.gone targeted inactivation of the wild-type allele. The
To determine whether these cells have the capacityundifferentiated AML12/2 ES cell clones were morpho-
to differentiate into hematopoietic lineages within thelogically indistinguishable from AML11/2 ES cells and
had similar growth rates. Four independent AML12/2 ES context of an intact animal, AML12/2 ES cells were in-
AML1 Is Required for Fetal Liver Hematopoiesis
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Figure 4. Histologic Analysis of the Hemato-
poietic System of a Control and Mutant Em-
bryos at E11.5±E12.5.
(A) Sections of livers from an E11.5 control
(1/2) embryo contained numerous dark-
staining hematopoietic elements. In contrast,
sections of the AML12/2 mutant (2/2) embryo
revealed the complete absence of hemato-
poietic precursors, with only rare primitive
nucleated erythrocytes seen within vessels
and sinusoids.
(B) Touch preparation of liver from a control
embryo contained numerous immature to
midmature erythroid cells, along with scat-
tered macrophages, immature myeloid cells,
andrare megakaryocytes (data not shown). In
contrast, liver touch preparation from AML1-
deficient mice contained primarily hepato-
cytes, with only scattered primitive nucleated
erythrocytes seen.
(C) Cytocentrifuge preparations of peripheral
blood from a viable E12.5 control embryo
contained primitive nucleated erythrocytes,
rare nonnucleated definitive erythrocytes, im-
mature myeloid elements, and numerous
platelets. Cytocentrifuge preparations from
peripheral blood of a viable E12.5 AML12/2
embryo consisted exclusively of nucleated
primitive erythrocytes with a complete ab-
sence of identifiable platelets.
jected into blastocysts, and chimeric animals were ana- in their ability to contribute to definitive hematopoiesis
and that this deficit is intrinsic to hematopoietic stemlyzed for the contribution of the ES cells to the tissues
of the mouse. The relative contribution of AML12/2 and cells or multipotential progenitors.
AML11/2 ES cells to chimeric animals, as estimated by
agouti coat color, was similar and typically ranged from
50% to 90%. The extent of contribution of the injected Discussion
ES cells to individual organs was determined by use
of glucose phosphate isomerase (GPI) isoform analysis Molecular analyses of leukemia-associated chromo-
somal rearrangements have indicated that the genes(Williams et al., 1994). The E14 ES cells contain the
GPI-1A isoform, whereas the C57BL/6 cells of the host encoding the AML1±CBFb transcription factor complex
are the most frequent target of translocations and inver-embryo are GPI-1B isoform specific. We examined 13
different tissues from 1-month-old chimeric mice, and sions in human leukemia (for reviews see Nucifora and
Rowley, 1995; Liu et al., 1995; Meyers and Hiebert, 1996).representative results are illustrated in Figure 6. AML12/2
ES cells failed to contribute to bone marrow, spleen, AML1±CBFb directly binds the enhancer core motif and
has been shown to regulate expression of a variety ofthymus, or peripheral blood, whereas they had consider-
able contribution to all of the nonhematopoietic organs hematopoietic specific genes, suggesting that it is likely
to play an important role in normal hematopoietic devel-examined. By contrast, AML11/2 ES cells contributed to
all tissues, including sites of hematopoiesis. These data opment (Meyers and Hiebert, 1996). Using AML1-defi-
cient mice, we now demonstrate that expression ofsuggest that AML12/2 ES cells have a selective defect
Table 2. Hematopoietic Progenitors in Yolk Sac and Fetal Liver
Yolk Sac a (E10.5) Fetal Liverb (E11.5)
AML1 (n) E M Mix AML1 (n) E M Mix
1/1 (5) 114 6 34 296 6 83 62 6 27 1/1 (9) 11 6 4 92 6 28 18 6 3
1/2 (5) 152 6 48 280 6 47 93 6 37 1/2 (14) 11 6 5 92 6 23 17 6 6
2/2 (4) 0 0 0 2/2 (7) 0 0 0
Abbreviations: n, numbers of embryos analyzed; E, erythroid colonies; M, myeloid colonies; Mix, erythroid±myeloid mixed colonies.
a Numbers represent colonies per yolk sac, mean 6 SD.
b Numbers represent colonies per 5 3 103 fetal liver cells, mean 6 SD.
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derived hematopoiesis within the AML1-deficient em-
bryos suggests a primary defect in the developmental
program of stem cells responsible for establishing defin-
itive hematopoiesis. Although the presented results do
not directly address the nature of this defect, possibilit-
ies include an inability of the AML1-deficient animals to
generate stem cells capable of establishing definitive
hematopoiesis or, alternatively, an inability of stem cells
or multipotential progenitors to activate AML1±CBFb
target genes that are crucial for proper differentiation
or proliferation. A number of putative AML1-regulated
targets have been identified, including the hematopoi-
etic growth factors IL-3 and GM-CSF (Shoemaker et
al., 1990; Takahashi et al., 1995) and the growth factor
receptor for CSF1 (Zhang et al., 1994); however, it is
unlikely that the loss of expression of any of these genes
is mechanistically involved in the observed phenotype.
Mice carrying a targeted mutation in the GM-CSF gene
Figure 5. Embryoid Bodies Derived from Control and AML1-Defi-
have normal steady-state hematopoiesis but developcient ES Cells
pulmonary alveolar proteinosis (Dranoff et al., 1994;(A) Hemoglobinized embryoid bodies were observed in cultures of
Stanley et al.,1994). An autosomal recessive inactivatingboth AML11/2 and AML12/2 ES cells.
mutation in the gene encoding the CSF1 receptor ligand(B) Cytocentrifuge preparations of single embryoid bodies from
control (1/2) and mutant (2/2) derived cultures. is the underlying defect in osteopetrotic (op/op) mice
(Yoshida et al., 1990). These animals are characterized
by impaired mononuclear phagocyte development andAML1 is essential for the establishment of definitive he-
a deficiency of osteoclasts that results in an increasematopoiesis of all lineages. AML1-deficient embryos
in bone density and occlusion of the marrow cavity.showed normalmorphogenesis and had activeyolk sac±
Moreover, mice with mutations in both the GM-CSF andderived primitive erythropoiesis; however, they lacked
CSF1 genes present with features corresponding todefinitive hematopoietic progenitors in both the yolk sac
mice deficient in either factor alone, with the predomi-and fetal liver and failed to develop fetal liver hematopoi-
nant hematopoietic defect being a deficiency of matureesis. As a result of this hematopoietic defect, the
macrophages (Lieschke et al., 1994). Similarly, IL-3 isAML12/2 embryos died during midembryonic develop-
not thought to play a major role in the regulation ofment, secondary to hemorrhages within the brain, peri-
embryonic hematopoietic stem cells and is expressedcardium, and peritoneum that presumably resulted from
primarily by activated T cells, which appear well afteran absence of circulating platelets, compounded by an
establishment of fetal liver hematopoiesis (for review seeapparently evolving anemia resulting from an inability
Ihle, 1992). Therefore, it is likely that additional AML1-to produce definitive nonnucleated erythrocytes. More-
regulated target genes remain to be identified and thatover, the underlying hematopoietic defect resulting from
these target genes will function as components in signalthe loss of AML1 was cell autonomous in that AML12/2
transduction pathways critical for the normal survival,ES cells failed to contribute toany hematopoietic tissues
proliferation, or differentiation of hematopoietic stemin the normal microenvironment of chimeric mice.
The presence of normal primitive yolk sac hematopoi- cells that are responsible for establishing definitive he-
esis along with the complete absence of fetal liver± matopoiesis.
The phenotype resulting from the loss of AML1 is
distinct from the consequences of targeted mutations
in a number of other genes implicated in hematopoietic
development (Orkin, 1995). Mice with null mutations in
either tal1/SCL (Shivdasani et al., 1995) or rbtn2 (Warren
et al., 1994) die during early embryonic development
from severe anemia that results from the complete ab-
sence of primitive yolk sac±derived erythropoiesis. Simi-
larly, GATA1-deficient ES cellsdo not contribute to prim-
itive erythropoiesis in chimeric animals or in vitro (Pevny
et al., 1991; Simon et al., 1992; Weiss et al., 1994). By
contrast, mutations in GATA2 lead to an early embryonic
Figure 6. Contribution of AML11/2 and AML12/2 ES cells to Tissues death as a result of impairment of both primitive and
in Chimeric Animals definitive erythropoiesis (Tsai et al., 1994).
GPI analysis of chimeric animals derived from three AML11/2 (A±C) Inactivation of two genes implicated in myeloid differ-
and three AML12/2 (D±F) ES cell clones. ES cells contain the GPI- entiation, c-myb and PU.1, results in phenotypes that
1A isoform, whereas the host contains the GPI-1B isoform. Results
more closely resemble the effects observed in AML1-from the following tissues are illustrated: kidney (K), thymus (T), liver
deficient mice (Mucenski et al., 1991; Scott et al., 1994).(L), spleen (S), bone marrow (BM), peripheral blood (B), and skeletal
muscle (SM). WT, wild type. Homozygous loss of c-myb, like AML1, results in normal
AML1 Is Required for Fetal Liver Hematopoiesis
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yolk sac±derived erythropoiesis, but a severe defect in could in part be the result of noncritical functions for
AML1 in these tissues, or, alternatively, its function isfetal liver hematopoiesis (Mucenski et al., 1991). The
redundant and can be complemented by other AML1major difference from the phenotypic consequences
family members. Along these lines, it is curious thatresulting from the loss of AML1 is that livers from
bleeding appears to initiate within the cranial nerve gan-c-myb-deficient mice retain hematopoietic progenitors,
glia of the AML1-deficient embryos. Either these struc-although at markedly reduced numbers compared to
tures are uniquely susceptible to bleeding at this stagecontrols. In addition, mice lacking c-myb have normal
of embryonic development or AML1 provides an essen-megakaryocytic development and hence do not die from
tial function within these cells. No morphologic abnor-bleeding, but succumb to complications of anemia
malities were observed in cells of the nervous systemsomewhat later in development. Similarly, loss of PU.1,
of the AML1-deficient mice, and thus we are unable ata member of the Ets-like family of transcription factors,
present to address this latter issue. Detailed analysis ofresults in impaired fetal liver hematopoiesis; however,
the expression pattern of AML1, AML2, and AML3duringthis defect also appears to spare megakaryocytes and
embryogenesis in both wild-type and mutant animalsto be less severe in the erythroid lineage (Scott et al.,
should help to clarify these questions.1994). These mice die from anemia at an even later stage
In summary, our results demonstrate that the AML1±of development than the c-myb-deficient mice. The
CBFb transcription factor complex plays a pivotal roleclose relationship among the phenotype of mice that
in regulating the transcription of genes that are essentiallack AML1, c-myb, or PU.1 is interesting given that AML1
for definitive hematopoiesis. The frequent targeting ofcooperates with c-Myb- and Ets-like family members
this complex by leukemia-associated chromosomal re-in regulating the tissue-specific expression of several
arrangements suggests that alteration of its activityhematopoietic-specific genes (Wotton et al., 1994; Her-
leads to the disruption of AML1-mediated signals, whichnandez-Munain and Krangel,1995). It is likely that AML1,
are critical for normal growth control or differentiation.c-Myb, and Ets-like proteins coordinately regulate par-
We speculate that AML1 functions as a master switchtially overlapping sets of genes. The observed pheno-
that controls the ability of hematopoietic stem cells totypes suggest that target genes regulated by AML1 ap-
differentiate into definitive hematopoietic elements. Al-pear to be essential for the development of definitive
terations in its activity may result in a block in differentia-hematopoiesis of all lineages, whereas c-Myb and PU.1
tion that leads to an increase in proliferating hematopoi-target genes are necessary in a more restricted set of
etic progenitors that are prone to acquire secondarylineages.
mutations that eventually result in malignant transfor-More recently, targeted disruption of the GATA3 tran-
mation.scription factor was shown to result in a phenotype that
is, in part, similar to that seen in the AML12/2 embryos
(Pandolfi et al., 1995). GATA3-deficient embryos die be- Experimental Procedures
tween E11 and E12 from massive internal bleeding and
Construction of AML1 Targeting Vectorshave markedly suppressed fetal liver hematopoiesis;
To construct pKO4-4-hygrB, overlapping AML1 genomic clones
however, these mice display normal yolk sac definitive were isolated from a phage library made from strain 129±derived
hematopoiesis, and their fetal livers contain erythroid CCE ES cell DNA (van Deursen et al., 1992), and an 8 kb fragment
precursors and normal megakaryocytes. In addition, containing exon 4 was subcloned into pBluescript (Stratagene). A
2 kb hygrBR cassette (van Deursen et al., 1991) was used to replaceGATA32/2 embryos show markedgrowth retardation and
a 28 bp unique AatII fragment containing 8 bp of intron 3 and 20severe deformities of the brain and spinal cord. These
bp of exon 4 and was oriented inthe opposite transcriptional orienta-data suggest that GATA3 is required for later stages of
tion to the AML1 gene. An additional 3 kb fragment that included
hematopoietic development than is AML1 and that it intron 3 sequence was then ligated to the 59 end of the construct.
has critical functions outside of hematopoietic tissues. Finally, a 2 kb HSV±thymidine kinase (tk) cassette (van Deursen and
Weiringa, 1992) was added to the 39 end of the construct. The vectorThus, among the transcription factors implicated in he-
was linearized at a unique SalI site, 39 to the tk sequences prior tomatopoietic development (Orkin, 1995), AML1 appears
introduction in ES cells. The construct for the second round of geneto provide unique functions in the establishment of de-
targeting, pKO4-4-neo, was constructed as described above except
finitive hematopoiesis of all lineages. that the hygrBR gene was replaced by a neoR gene obtained from
The fact that loss of AML1 resulted in a phenotype pRC/RSV (Invitrogen). This substitution introduced an XbaI restric-
tion site, 59 to the neoR cassette, which was used to discriminateconfined to the hematopoietic system at E12.5 was
the targeted AML1 alleles by Southern blot analysis.somewhat surprising given the high degree of homology
of AML1 to the Drosophila gene runt (Erickson et al.,
Generation of AML1 Mutant Mice1992). runt is a pair-rule gene involved in establishing
E14 ES cells were cultured in 60% BRL-conditioned medium (Smiththe positional identities of individual blastoderm cells
and Hooper, 1987) supplemented with 1000 U/ml mouse recombi-during Drosophila embryogenesis, and its mutation
nant LIF (GIBCO BRL); 50 mg/ml SalI-linearized targeting vector,
leads to segmentation defects and lethality (Gergen and pKO4-4-hygrB or pKO4-4-neo, was electroporated into 1.5 3 107
Wieschaus, 1985; Gergen and Wieschaus, 1986). In ad- ES cells in 2 ml of phosphate-buffered saline (PBS) at 230 V and
500 mF. Selection was initiated 24 hr later by adding 90 U/ml hygrBdition, it has been shown to function in Drosophila sex
(Calbiochem) and 2 mM GANC (Syntex) or, in the second round ofdetermination and neural development (Duffy and Ger-
targeting, by the further addition of 125 mg/ml G418 (GIBCO BRL),gen, 1991; Kania et al., 1990). Moreover, murine AML1
and selection was continued for 8 days. Doubly or triply resistant
is widely expressed in a large number of tissues and clones were analyzed by Southern blot analysis for evidence of
cell types (Miyoshi et al., 1995). The absence of a more homologous recombination. Southern blots of XbaI-digested geno-
mic DNA were hybridized with a 0.4 kb 59 or a 0.5 kb 39 AML1widespread phenotype in the AML1-deficient mice
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genomic fragment that corresponded to genomic sequences out- 300 V at 48C. Following electrophoresis, membranes were stained
with 10 ml of a 0.9% agarose solution that contained 5 mM mag-side of the vector. ES cell clones with normal karyotypes were used
for injections into C57BL/6 blastocysts. Male chimeras were bred nesium acetate, 15 mg of fructose-6-phosphate, 2 mg of methylthia-
zolium tetrazolium, 0.36 mg of phenazine methosulfate, 2 mg ofwith C57BL/6 females, and germline transmission of the ES cell±
derived genotype was assessed by coat color. Tail biopsies of agouti nicotinamide adenine dinucleotide phosphate, and 10 U of glucose-
6-phosphate dehydrogenase, and bands appeared in 10±15 minoffspring were screened for the disrupted AML1 gene by Southern
blot analysis as previously described (Okuda et al., 1995). (Williams et al., 1994).
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